E Fund Management’s iTeos Therapeutics ITOS Stock Holding History

E Fund Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,236	Closed	-$231K	–	336
2022 Q2	$231K	Buy	+11,236	New	+$267K	0.02%	272

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

E Fund Management's ITOS Position: Q3 2022 in Review

E Fund Management sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 11,236 shares — an estimated $231K sold.

E Fund Management first reported a position in ITOS in Q2 2022 and held it in 1 quarter. The position peaked at $231K in Q2 2022. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

E Fund Management reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
E Fund Management sold 11,236 iTeos Therapeutics shares in Q3 2022, an estimated $231K.
E Fund Management first reported a position in iTeos Therapeutics in Q2 2022 and held it in 1 quarter.
E Fund Management's iTeos Therapeutics position peaked at $231K in Q2 2022.
143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on E Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.